



REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2014	2013	% Change			2014	2013	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
CONSUMER SEGMENT ⁽²⁾										
BABY CARE										
US	\$ 107	106	0.9%	0.9%	-	\$ 209	209	0.0%	0.0%	-
Intl	500	480	4.2%	8.6%	-4.4%	943	941	0.2%	5.5%	-5.3%
WW	607	586	3.6%	7.2%	-3.6%	1,152	1,150	0.2%	4.6%	-4.4%
ORAL CARE										
US	142	149	-4.7%	-4.7%	-	302	307	-1.6%	-1.6%	-
Intl	271	257	5.4%	7.3%	-1.9%	522	502	4.0%	7.2%	-3.2%
WW	413	406	1.7%	2.9%	-1.2%	824	809	1.9%	3.9%	-2.0%
OTC										
US	316	290	9.0%	9.0%	-	682	644	5.9%	5.9%	-
Intl	687	641	7.2%	7.4%	-0.2%	1,332	1,330	0.2%	1.7%	-1.5%
WW	1,003	931	7.7%	7.8%	-0.1%	2,014	1,974	2.0%	3.0%	-1.0%
SKIN CARE										
US	506	463	9.3%	9.3%	-	963	916	5.1%	5.1%	-
Intl	462	445	3.8%	4.2%	-0.4%	919	894	2.8%	4.4%	-1.6%
WW	968	908	6.6%	6.8%	-0.2%	1,882	1,810	4.0%	4.8%	-0.8%
WOMEN'S HEALTH										
US	11	84	-86.9%	-86.9%	-	35	165	-78.8%	-78.8%	-
Intl	331	327	1.2%	5.4%	-4.2%	634	647	-2.0%	3.3%	-5.3%
WW	342	411	-16.8%	-13.5%	-3.3%	669	812	-17.6%	-13.4%	-4.2%
WOUND CARE/OTHER										
US	238	234	1.7%	1.7%	-	438	433	1.2%	1.2%	-
Intl	173	182	-4.9%	-4.4%	-0.5%	322	345	-6.7%	-5.4%	-1.3%
WW	411	416	-1.2%	-1.0%	-0.2%	760	778	-2.3%	-1.7%	-0.6%
TOTAL CONSUMER										
US	1,320	1,326	-0.5%	-0.5%	-	2,629	2,674	-1.7%	-1.7%	-
Intl	2,424	2,332	3.9%	5.8%	-1.9%	4,672	4,659	0.3%	3.3%	-3.0%
WW	\$ 3,744	3,658	2.4%	3.6%	-1.2%	\$ 7,301	7,333	-0.4%	1.5%	-1.9%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

PHARMACEUTICAL SEGMENT ^{(2) (3)}

IMMUNOLOGY

	SECOND QUARTER					SIX MONTHS				
	2014	2013	% Change			2014	2013	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
US	\$ 1,853	1,578	17.4%	17.4%	-	\$ 3,400	3,217	5.7%	5.7%	-
Intl	778	663	17.3%	19.1%	-1.8%	1,574	1,228	28.2%	31.8%	-3.6%
WW	2,631	2,241	17.4%	17.9%	-0.5%	4,974	4,445	11.9%	12.9%	-1.0%
REMICADE										
US	1,021	926	10.3%	10.3%	-	2,018	1,896	6.4%	6.4%	-
US Exports ⁽⁴⁾	357	332	7.5%	7.5%	-	524	681	-23.1%	-23.1%	-
Intl	426	414	2.9%	6.3%	-3.4%	872	695	25.5%	31.0%	-5.5%
WW	1,804	1,672	7.9%	8.7%	-0.8%	3,414	3,272	4.3%	5.5%	-1.2%
SIMPONI/SIMPONI ARIA										
US	132	87	51.7%	51.7%	-	236	181	30.4%	30.4%	-
Intl	150	88	70.5%	71.3%	-0.8%	305	231	32.0%	34.7%	-2.7%
WW	282	175	61.1%	61.5%	-0.4%	541	412	31.3%	32.8%	-1.5%
STELARA										
US	343	233	47.2%	47.2%	-	622	459	35.5%	35.5%	-
Intl	185	138	34.1%	31.4%	2.7%	362	258	40.3%	39.2%	1.1%
WW	528	371	42.3%	41.3%	1.0%	984	717	37.2%	36.8%	0.4%
OTHER IMMUNOLOGY										
US	-	-	-	-	-	-	-	-	-	-
Intl	17	23	-26.1%	-22.7%	-3.4%	35	44	-20.5%	-14.6%	-5.9%
WW	17	23	-26.1%	-22.7%	-3.4%	35	44	-20.5%	-14.6%	-5.9%
INFECTIOUS DISEASES										
US	1,020	259	*	*	-	1,581	497	*	*	-
Intl	742	711	4.4%	3.5%	0.9%	1,381	1,288	7.2%	6.6%	0.6%
WW	1,762	970	81.6%	80.9%	0.7%	2,962	1,785	65.9%	65.5%	0.4%
EDURANT										
US	6	3	100.0%	100.0%	-	11	6	83.3%	83.3%	-
Intl	86	53	62.3%	57.7%	4.6%	162	93	74.2%	70.3%	3.9%
WW	92	56	64.3%	60.0%	4.3%	173	99	74.7%	71.0%	3.7%
INCIVO										
US	-	-	-	-	-	-	-	-	-	-
Intl	97	172	-43.6%	-42.5%	-1.1%	183	334	-45.2%	-44.8%	-0.4%
WW	97	172	-43.6%	-42.5%	-1.1%	183	334	-45.2%	-44.8%	-0.4%
OLYSIO/SOVRIAD										
US	725	-	*	*	-	1,016	-	*	*	-
Intl	106	-	*	*	0.0%	169	-	*	*	0.0%
WW	831	-	*	*	0.0%	1,185	-	*	*	0.0%
PREZISTA										
US	239	196	21.9%	21.9%	-	453	363	24.8%	24.8%	-
Intl	253	239	5.9%	4.7%	1.2%	484	439	10.3%	9.6%	0.7%
WW	492	435	13.1%	12.4%	0.7%	937	802	16.8%	16.4%	0.4%
OTHER INFECTIOUS DISEASES										
US	50	60	-16.7%	-16.7%	-	101	128	-21.1%	-21.1%	-
Intl	200	247	-19.0%	-19.6%	0.6%	383	422	-9.2%	-9.0%	-0.2%
WW	250	307	-18.6%	-19.0%	0.4%	484	550	-12.0%	-11.9%	-0.1%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2014	2013	% Change			2014	2013	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
NEUROSCIENCE										
US	600	626	-4.2%	-4.2%	-	1,201	1,372	-12.5%	-12.5%	-
Intl	1,027	1,054	-2.6%	-2.4%	-0.2%	2,064	2,052	0.6%	2.5%	-1.9%
WW	1,627	1,680	-3.2%	-3.1%	-0.1%	3,265	3,424	-4.6%	-3.5%	-1.1%
CONCERTA/METHYLPHENIDATE										
US	28	85	-67.1%	-67.1%	-	63	224	-71.9%	-71.9%	-
Intl	117	130	-10.0%	-8.3%	-1.7%	232	247	-6.1%	-3.0%	-3.1%
WW	145	215	-32.6%	-31.6%	-1.0%	295	471	-37.4%	-35.8%	-1.6%
INVEGA										
US	89	76	17.1%	17.1%	-	175	147	19.0%	19.0%	-
Intl	69	74	-6.8%	-7.5%	0.7%	148	135	9.6%	11.3%	-1.7%
WW	158	150	5.3%	5.0%	0.3%	323	282	14.5%	15.3%	-0.8%
INVEGA SUSTENNA/ XEPLION										
US	202	158	27.8%	27.8%	-	384	322	19.3%	19.3%	-
Intl	192	132	45.5%	42.3%	3.2%	383	252	52.0%	51.0%	1.0%
WW	394	290	35.9%	34.4%	1.5%	767	574	33.6%	33.2%	0.4%
RISPERDAL CONSTA										
US	110	107	2.8%	2.8%	-	216	213	1.4%	1.4%	-
Intl	192	229	-16.2%	-17.7%	1.5%	396	458	-13.5%	-13.4%	-0.1%
WW	302	336	-10.1%	-11.1%	1.0%	612	671	-8.8%	-8.7%	-0.1%
OTHER NEUROSCIENCE										
US	171	200	-14.5%	-14.5%	-	363	466	-22.1%	-22.1%	-
Intl	457	489	-6.5%	-4.9%	-1.6%	905	960	-5.7%	-2.4%	-3.3%
WW	628	689	-8.9%	-7.8%	-1.1%	1,268	1,426	-11.1%	-8.9%	-2.2%
ONCOLOGY										
US	278	206	35.0%	35.0%	-	518	405	27.9%	27.9%	-
Intl	833	679	22.7%	21.6%	1.1%	1,615	1,274	26.8%	27.1%	-0.3%
WW	1,111	885	25.5%	24.6%	0.9%	2,133	1,679	27.0%	27.2%	-0.2%
VELCADE										
US	-	-	-	-	-	-	-	-	-	-
Intl	403	379	6.3%	6.2%	0.1%	811	732	10.8%	12.2%	-1.4%
WW	403	379	6.3%	6.2%	0.1%	811	732	10.8%	12.2%	-1.4%
ZYTIGA										
US	235	174	35.1%	35.1%	-	464	335	38.5%	38.5%	-
Intl	327	221	48.0%	45.1%	2.9%	610	404	51.0%	49.4%	1.6%
WW	562	395	42.3%	40.7%	1.6%	1,074	739	45.3%	44.4%	0.9%
OTHER ONCOLOGY										
US	43	32	34.4%	34.4%	-	54	70	-22.9%	-22.9%	-
Intl	103	79	30.4%	29.2%	1.2%	194	138	40.6%	40.7%	-0.1%
WW	146	111	31.5%	30.6%	0.9%	248	208	19.2%	19.2%	0.0%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2014	2013	% Change			2014	2013	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
<u>TOTAL OTHER</u>										
US	862	708	21.8%	21.8%	-	1,653	1,357	21.8%	21.8%	-
Intl	516	541	-4.6%	-4.7%	0.1%	1,020	1,103	-7.5%	-6.7%	-0.8%
WW	1,378	1,249	10.3%	10.3%	0.0%	2,673	2,460	8.7%	9.0%	-0.3%
<u>PROCRIT/EPREX</u>										
US	178	190	-6.3%	-6.3%	-	354	423	-16.3%	-16.3%	-
Intl	141	145	-2.8%	-3.4%	0.6%	275	290	-5.2%	-5.0%	-0.2%
WW	319	335	-4.8%	-5.1%	0.3%	629	713	-11.8%	-11.7%	-0.1%
<u>XARELTO</u>										
US	361	189	91.0%	91.0%	-	680	347	96.0%	96.0%	-
Intl	-	-	-	-	-	-	-	-	-	-
WW	361	189	91.0%	91.0%	-	680	347	96.0%	96.0%	-
<u>OTHER</u>										
US	323	329	-1.8%	-1.8%	-	619	587	5.5%	5.5%	-
Intl	375	396	-5.3%	-5.1%	-0.2%	745	813	-8.4%	-7.4%	-1.0%
WW	698	725	-3.7%	-3.6%	-0.1%	1,364	1,400	-2.6%	-2.0%	-0.6%
<u>TOTAL PHARMACEUTICAL</u>										
US	4,613	3,377	36.6%	36.6%	-	8,353	6,848	22.0%	22.0%	-
Intl	3,896	3,648	6.8%	6.9%	-0.1%	7,654	6,945	10.2%	11.6%	-1.4%
WW	<u>\$ 8,509</u>	<u>7,025</u>	21.1%	21.1%	0.0%	<u>\$ 16,007</u>	<u>13,793</u>	16.1%	16.8%	-0.7%

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	SECOND QUARTER					SIX MONTHS				
	2014	2013	% Change			2014	2013	% Change		
			Reported	Operational ⁽¹⁾	Currency			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES AND DIAGNOSTICS ^{(2) (3)}										
CARDIOVASCULAR CARE										
US	\$ 214	204	4.9%	4.9%	-	\$ 419	402	4.2%	4.2%	-
Intl	353	325	8.6%	8.7%	-0.1%	689	640	7.7%	9.1%	-1.4%
WW	567	529	7.2%	7.3%	-0.1%	1,108	1,042	6.3%	7.2%	-0.9%
DIABETES CARE										
US	222	259	-14.3%	-14.3%	-	414	542	-23.6%	-23.6%	-
Intl	336	330	1.8%	1.8%	0.0%	656	647	1.4%	2.4%	-1.0%
WW	558	589	-5.3%	-5.3%	0.0%	1,070	1,189	-10.0%	-9.5%	-0.5%
DIAGNOSTICS										
US	232	241	-3.7%	-3.7%	-	456	489	-6.7%	-6.7%	-
Intl	229	242	-5.4%	-4.3%	-1.1%	448	471	-4.9%	-2.6%	-2.3%
WW	461	483	-4.6%	-4.1%	-0.5%	904	960	-5.8%	-4.7%	-1.1%
ORTHOPAEDICS										
US	1,294	1,274	1.6%	1.6%	-	2,586	2,535	2.0%	2.0%	-
Intl	1,175	1,111	5.8%	5.3%	0.5%	2,304	2,235	3.1%	4.1%	-1.0%
WW	2,469	2,385	3.5%	3.3%	0.2%	4,890	4,770	2.5%	3.0%	-0.5%
SPECIALTY SURGERY/OTHER ⁽⁵⁾										
US	424	426	-0.5%	-0.5%	-	841	830	1.3%	1.3%	-
Intl	481	464	3.7%	4.7%	-1.0%	938	899	4.3%	6.8%	-2.5%
WW	905	890	1.7%	2.2%	-0.5%	1,779	1,729	2.9%	4.2%	-1.3%
SURGICAL CARE										
US	551	577	-4.5%	-4.5%	-	1,090	1,108	-1.6%	-1.6%	-
Intl	1,024	1,011	1.3%	1.9%	-0.6%	1,993	1,988	0.3%	2.1%	-1.8%
WW	1,575	1,588	-0.8%	-0.4%	-0.4%	3,083	3,096	-0.4%	0.8%	-1.2%
VISION CARE										
US	262	262	0.0%	0.0%	-	548	543	0.9%	0.9%	-
Intl	445	468	-4.9%	-4.0%	-0.9%	920	927	-0.8%	2.9%	-3.7%
WW	707	730	-3.2%	-2.7%	-0.5%	1,468	1,470	-0.1%	2.2%	-2.3%
TOTAL MEDICAL DEVICES AND DIAGNOSTICS										
US	3,199	3,243	-1.4%	-1.4%	-	6,354	6,449	-1.5%	-1.5%	-
Intl	4,043	3,951	2.3%	2.6%	-0.3%	7,948	7,807	1.8%	3.6%	-1.8%
WW	\$ 7,242	7,194	0.7%	0.9%	-0.2%	\$ 14,302	14,256	0.3%	1.3%	-1.0%

* Percentage greater than 100%

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Prior year amounts have been reclassified to conform to current year product disclosure

(4) Reported as U.S. sales

(5) Infection Prevention now reflected in Specialty Surgery/Other, previously reported independently